Home LiteratureArticle Details
PMID: 11250717 Published · ppublish English Journal Article Review

Metalloproteinases: role in breast carcinogenesis, invasion and metastasis.

Breast cancer research : BCR ·Vol. 2 ·No. 4 ·2000-00-00 ·Pages 252-7

Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N

Abstract

The matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases. Their primary function is degradation of proteins in the extracellular matrix. Currently, at least 19 members of this family are known to exist. Based on substrate specificity and domain organization, the MMPs can be loosely divided into four main groups: the interstitial collagenases, gelatinases, stromelysins and membrane-type MMPs. Recent data from model systems suggest that MMPs are involved in breast cancer initiation, invasion and metastasis. Consistent with their role in breast cancer progression, high levels of at least two MMPs (MMP-2 and stromelysin-3) have been found to correlate with poor prognosis in patients with breast cancer. Because MMPs are apparently involved in breast cancer initiation and dissemination, inhibition of these proteinases may be of value both in preventing breast cancer and in blocking metastasis of established tumours

MeSH Terms
Apoptosis Basement Membrane/metabolism Biomarkers, Tumor Breast Neoplasms/drug therapy,enzymology,genetics,pathology Disease Progression Extracellular Matrix Proteins/metabolism Female Growth Substances/metabolism Humans Metalloendopeptidases/antagonists & inhibitors,chemistry,classification,genetics,physiology Neoplasm Invasiveness Neoplasm Metastasis Neoplasm Proteins/antagonists & inhibitors,chemistry,classification,genetics,physiology Neovascularization, Pathologic/enzymology Prognosis Protease Inhibitors/therapeutic use Protein Structure, Tertiary Receptors, Growth Factor/metabolism Substrate Specificity
Chemicals
Biomarkers, Tumor Extracellular Matrix Proteins Growth Substances Neoplasm Proteins Protease Inhibitors Receptors, Growth Factor Metalloendopeptidases
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Duffy M J
Department of Nuclear Medicine, St Vincent's Hospital, Dublin, Ireland. Michael.J.Duffy@ucd.ie
Maguire T M
Hill A
McDermott E
O'Higgins N
References (47)
47 references, click to expand
  1. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer.
    Int J Cancer. 1999 Feb 19;84(1):44-8 PMID: 9988231
  2. Fas-mediated apoptosis in Ewing's sarcoma cell lines by metalloproteinase inhibitors.
    J Natl Cancer Inst. 1999 Oct 6;91(19):1678-84 PMID: 10511596
  3. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3.
    Br J Cancer. 1999 Mar;79(9-10):1347-55 PMID: 10188875
  4. Expression and regulation of collagenase-3 (MMP-13) in human malignant tumors.
    APMIS. 1999 Jan;107(1):45-53 PMID: 10190279
  5. Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation.
    APMIS. 1999 Jan;107(1):111-9 PMID: 10190287
  6. Cancer invasion and tissue remodeling--cooperation of protease systems and cell types.
    APMIS. 1999 Jan;107(1):120-7 PMID: 10190288
  7. An odyssey from breast to bone: multi-step control of mammary metastases and osteolysis by matrix metalloproteinases.
    APMIS. 1999 Jan;107(1):128-36 PMID: 10190289
  8. Membrane-type matrix metalloproteinases.
    APMIS. 1999 Jan;107(1):137-43 PMID: 10190290
  9. Clinical studies with matrix metalloproteinase inhibitors.
    APMIS. 1999 Jan;107(1):174-80 PMID: 10190295
  10. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention.
    J Clin Invest. 1999 May;103(9):1237-41 PMID: 10225966
  11. Metalloprotease-mediated ligand release regulates autocrine signaling through the epidermal growth factor receptor.
    Proc Natl Acad Sci U S A. 1999 May 25;96(11):6235-40 PMID: 10339571
  12. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis.
    Cell. 1999 Jul 23;98(2):137-46 PMID: 10428026
  13. Activity of type IV collagenases in benign and malignant breast disease.
    Br J Cancer. 1993 May;67(5):1126-31 PMID: 8494711
  14. The 28-kDa N-terminal domain of mouse stromelysin-3 has the general properties of a weak metalloproteinase.
    J Biol Chem. 1993 Jul 25;268(21):15435-41 PMID: 8340372
  15. Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3.
    J Biol Chem. 1994 Oct 14;269(41):25849-55 PMID: 7523394
  16. Furin-dependent intracellular activation of the human stromelysin-3 zymogen.
    Nature. 1995 May 18;375(6528):244-7 PMID: 7746327
  17. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice.
    J Natl Cancer Inst. 1995 Oct 18;87(20):1546-50 PMID: 7563189
  18. Invasive phenotype of MCF10A cells overexpressing c-Ha-ras and c-erbB-2 oncogenes.
    Int J Cancer. 1995 Dec 11;63(6):815-22 PMID: 8847140
  19. A single ets-related transcription factor, E1AF, confers invasive phenotype on human cancer cells.
    Oncogene. 1996 Jan 18;12(2):221-7 PMID: 8570199
  20. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94).
    Cancer Res. 1996 Jun 15;56(12):2815-22 PMID: 8665519
  21. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1.
    Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7069-74 PMID: 8692946
  22. The role of stromelysin-1 in stromal-epithelial interactions and cancer.
    Enzyme Protein. 1996;49(1-3):174-81 PMID: 8797005
  23. The biochemistry of metastasis.
    Adv Clin Chem. 1996;32:135-66 PMID: 8899072
  24. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules.
    J Biol Chem. 1997 Jan 24;272(4):2446-51 PMID: 8999957
  25. Misregulation of stromelysin-1 expression in mouse mammary tumor cells accompanies acquisition of stromelysin-1-dependent invasive properties.
    J Biol Chem. 1997 Feb 21;272(8):5007-15 PMID: 9030563
  26. Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer.
    Eur J Cancer. 1996 Dec;32A(14):2528-33 PMID: 9059343
  27. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.
    J Clin Invest. 1997 May 15;99(10):2509-17 PMID: 9153295
  28. Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4.
    Oncogene. 1997 Jun 12;14(23):2767-74 PMID: 9190892
  29. The urokinase-type plasminogen activator system in cancer metastasis: a review.
    Int J Cancer. 1997 Jul 3;72(1):1-22 PMID: 9212216
  30. Changing views of the role of matrix metalloproteinases in metastasis.
    J Natl Cancer Inst. 1997 Sep 3;89(17):1260-70 PMID: 9293916
  31. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis.
    Int J Cancer. 1998 Jan 19;75(2):246-53 PMID: 9462715
  32. Angiogenesis and tumor metastasis.
    Annu Rev Med. 1998;49:407-24 PMID: 9509272
  33. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy.
    J Cell Biol. 1998 Mar 23;140(6):1535-41 PMID: 9508784
  34. Matrix metalloproteinases in cancer: prognostic markers and targets for therapy (review).
    Int J Oncol. 1998 Jun;12(6):1343-8 PMID: 9592197
  35. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies.
    Clin Cancer Res. 1998 May;4(5):1101-9 PMID: 9607566
  36. Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma.
    Cancer. 1998 Sep 15;83(6):1153-62 PMID: 9740080
  37. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3.
    FEBS Lett. 1998 Sep 11;435(1):39-44 PMID: 9755855
  38. High levels of TIMP-2 correlate with adverse prognosis in breast cancer.
    Int J Cancer. 2000 Mar 20;89(2):118-21 PMID: 10756061
  39. Stromelysin-3 in the biology of the normal and neoplastic mammary gland.
    J Mammary Gland Biol Neoplasia. 1996 Apr;1(2):231-40 PMID: 10887496
  40. Type IV collagenase immunoreactivity in invasive breast carcinoma.
    Lancet. 1983 Feb 5;1(8319):296-7 PMID: 6130313
  41. Do proteases play a role in cancer invasion and metastasis?
    Eur J Cancer Clin Oncol. 1987 May;23(5):583-9 PMID: 3308476
  42. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins.
    Cell. 1998 Oct 30;95(3):365-77 PMID: 9814707
  43. An essential role for ectodomain shedding in mammalian development.
    Science. 1998 Nov 13;282(5392):1281-4 PMID: 9812885
  44. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1.
    J Clin Invest. 1998 Dec 1;102(11):2002-10 PMID: 9835626
  45. The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis.
    Cancer Res. 1998 Dec 1;58(23):5500-6 PMID: 9850086
  46. Structure-function analysis of the ADAM family of disintegrin-like and metalloproteinase-containing proteins (review).
    J Protein Chem. 1999 May;18(4):447-65 PMID: 10449042
  47. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells.
    Cancer Res. 1999 Mar 15;59(6):1196-201 PMID: 10096547
Article Info
Journal
Breast cancer research : BCR
Abbr.
Breast Cancer Res
ISSN
1465-5411
DOI
10.1186/bcr65
Email
michael.j.duffy@ucd.ie
Published
2000-00-00
Epub
2000-00-07
Pages
252-7
Language
English
Region
England
NLM ID
100927353
PMCID
PMC138784
Subset
IM
External Links
PubMed source DOI: 10.1186/bcr65 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2